Akorn receives aNDA approval for ophthalmic solution

By Lisa Kerner

Erie, Pa., March 20 - Akorn, Inc. said it has received approval from the Food and Drug Administration for its abbreviated New Drug Application for Brimonidine Ophthalmic Solution, the first new product approval the company has received since its successful cGMP inspection last year.

"We are pleased to announce this new product approval," president and chief executive officer Arthur S. Przybyl said in a company news release.

"This product is representative of several other product submissions that are currently undergoing review by the FDA."

All of the products submitted for approval were through the company's Decatur facility, officials said.

Akorn, based in Buffalo Grove, Ill., manufactures and markets sterile specialty pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.